標(biāo)題: Titlebook: Drug Discovery in Africa; Impacts of Genomics, Kelly Chibale,Mike Davies-Coleman,Collen Masimirem Book 2012 Springer-Verlag Berlin Heidelbe [打印本頁] 作者: 二足動(dòng)物 時(shí)間: 2025-3-21 17:14
書目名稱Drug Discovery in Africa影響因子(影響力)
書目名稱Drug Discovery in Africa影響因子(影響力)學(xué)科排名
書目名稱Drug Discovery in Africa網(wǎng)絡(luò)公開度
書目名稱Drug Discovery in Africa網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Drug Discovery in Africa被引頻次
書目名稱Drug Discovery in Africa被引頻次學(xué)科排名
書目名稱Drug Discovery in Africa年度引用
書目名稱Drug Discovery in Africa年度引用學(xué)科排名
書目名稱Drug Discovery in Africa讀者反饋
書目名稱Drug Discovery in Africa讀者反饋學(xué)科排名
作者: 名字的誤用 時(shí)間: 2025-3-21 23:31 作者: 仔細(xì)閱讀 時(shí)間: 2025-3-22 02:24 作者: Solace 時(shí)間: 2025-3-22 06:16 作者: Hemodialysis 時(shí)間: 2025-3-22 09:58 作者: Myocarditis 時(shí)間: 2025-3-22 14:06
Searching for Drugs That Target Multiple Receptors for Anthelmintics from African Natural Products,ape Town. Researchers at these sites can take advantage of the chemical and biological diversity found in Africa to identify lead compounds for use against parasitic nematodes of local importance. The platform employs recombinant strains of yeast which express parasite proteins in a context that mak作者: Myocarditis 時(shí)間: 2025-3-22 17:39
Application of In Silico, In Vitro and In Vivo ADMET/PK Platforms in Drug Discovery,d if successful have, however, ensured the relevance and continued growth of the pharmaceutical industry. The major reasons for high attrition rates during drug discovery include lack of efficacy, toxicity, inadequate pharmacokinetics (PK), and market forces, factors which can be complexly interrela作者: Blood-Clot 時(shí)間: 2025-3-22 23:35 作者: 好開玩笑 時(shí)間: 2025-3-23 01:32
Natural Product-Based Drug Discovery Against Neglected Diseases with Special Reference to African Ne to private-sector research and development (R&D) investment. The discovery of antiparasitic new chemical entities (NCEs) based on ethnopharmacological approaches represents a major strategy for harnessing African biodiversity in the search for new drugs to combat NTDs as well as to address the ong作者: dowagers-hump 時(shí)間: 2025-3-23 08:20
,“Now I Heal with Pride”—The Application of Screens-to-Nature Technology to Indigenous Knowledge Sys innovation deficits in drug discovery. We describe the adaptation of a set of field-suitable bioassays, the “Screens-to-Nature” (STN) system, to a participatory research tool suitable for overcoming some of the difficulties in establishing cooperation between indigenous knowledge holders and scient作者: mechanical 時(shí)間: 2025-3-23 12:18
Innovative Approaches to Exploiting Traditional Medicines in Malaria,ies, especially those living in remote areas, rely on traditional medicine to treat the disease. Our research on ethnobotany-based malaria chemotherapy began in the 1990s following the sudden resurgence of the disease. Our work was first focused on drugs that could reverse chloroquine resistance in 作者: 包庇 時(shí)間: 2025-3-23 14:32
Anticancer Drug Repositioning Against Tropical Diseases: The Example of Methotrexate in the Treatmerged in South East Asia, and experience indicates that this resistance would eventually reach Africa, a scenario that would be associated with increased malaria morbidity and mortality. Thus, more than ever, new drugs are urgently needed. One of the strategies to discover new drugs is to reposition 作者: chance 時(shí)間: 2025-3-23 19:31 作者: 整體 時(shí)間: 2025-3-24 00:38
Random and Rational Approaches to HIV Drug Discovery in Africa,he virus as the causative agent of the acquired immune deficiency syndrome (AIDS). Within a short period of time thereafter, azidothymidine (AZT) was found to inhibit viral replication and became the first FDA-approved drug for the treatment of HIV/AIDS in 1987. Since then, continual and substantial作者: 讓你明白 時(shí)間: 2025-3-24 05:07
Structure-Based Design of Domain-Selective Angiotensin-Converting Enzyme Inhibitors,ve control of this disease. Angiotensin-converting enzyme (ACE) is a two-domain zinc metallopeptidase that plays a central role in the renin-angiotensin-aldosterone system and has thus been identified as a promising therapeutic target in the treatment of CVD and its major risk factor, hypertension. 作者: Lineage 時(shí)間: 2025-3-24 10:31
Natural Products and Antimalarial Drugs: Will Africa Provide the Next Major Breakthrough?,umerous plants that are reputed to have various medicinal properties, to date, not a single compound has been discovered in any African plant that has made it to clinical application in malaria chemotherapy. But Africa has the greatest malaria burden in the world. This chapter discusses previous and作者: SEMI 時(shí)間: 2025-3-24 10:47
Nanomedicine in the Development of Drugs for Poverty-Related Diseases,d bioavailability and thus reduced efficacy. In addition, there is lack of activity from the pharmaceutical industry due to the difficulty in refinancing the high development costs. Hence, new approaches have to be explored for the treatment of PRDs. Nanotechnology-based drug delivery systems (nanom作者: Allege 時(shí)間: 2025-3-24 15:48 作者: 收養(yǎng) 時(shí)間: 2025-3-24 19:19
rtunities, as well as a collection of strategies and techniq.Drug discovery originating in Africa has the potential to provide significantly improved treatment of endemic diseases such as malaria, tuberculosis and HIV/AIDS. This book critically reviews the current status of drug discovery research a作者: GRIEF 時(shí)間: 2025-3-24 23:44
Toshiyuki Moriuchi,Toshikazu Hiraoesiding off the more accessible southern African coast. A total of 18 South African marine natural products have been patented for their anti-cancer activity with the marine tube worm metabolite cephalostatin 1 and a synthetic analogue of the sponge metabolite hemiasterlin, showing the greatest promise for new drug development.作者: 符合規(guī)定 時(shí)間: 2025-3-25 05:40
Marine Bioprospecting in Southern Africa,esiding off the more accessible southern African coast. A total of 18 South African marine natural products have been patented for their anti-cancer activity with the marine tube worm metabolite cephalostatin 1 and a synthetic analogue of the sponge metabolite hemiasterlin, showing the greatest promise for new drug development.作者: MUT 時(shí)間: 2025-3-25 08:08
Natural Product-Based Drug Discovery in Africa: The Need for Integration into Modern Drug Discovery require a complete reevaluation of how natural product drug discovery is conducted on the continent, and in this chapter, we describe some of the components that could underpin this proposed transformation.作者: LATE 時(shí)間: 2025-3-25 14:56
Book 2012and HIV/AIDS. This book critically reviews the current status of drug discovery research and development in Africa, for diseases that are a major threat to the health of people living in Africa. Compiled by leading African and international experts, this book presents the science and strategies of m作者: RADE 時(shí)間: 2025-3-25 17:18 作者: fallible 時(shí)間: 2025-3-25 22:09
Apostolos P. Fournaris,Daniel M. Heinwe examine (1) how the toxicity of anticancers is just a matter of dose or “only dose makes the poison,” as coined in Paracelsus’ Law; (2) and the potential of the anticancer methotrexate to treat malaria, thus demonstrating that the opportunity exists to discover new antimalarials using the anticancer pharmacopoeia.作者: 連詞 時(shí)間: 2025-3-26 03:34 作者: NIB 時(shí)間: 2025-3-26 06:55 作者: 帶來 時(shí)間: 2025-3-26 09:06 作者: inhumane 時(shí)間: 2025-3-26 14:56
Targeting Conserved Pathways as a Strategy for Novel Drug Development: Disabling the Cellular Stres that allow HSP to be selectively targeted. In this chapter, we review the international status of this area of research and highlight progress by us and other African researchers towards the characterisation and targeting of HSP from humans and parasites from . and . as drug targets.作者: cumulative 時(shí)間: 2025-3-26 17:55
Anticancer Drug Repositioning Against Tropical Diseases: The Example of Methotrexate in the Treatmewe examine (1) how the toxicity of anticancers is just a matter of dose or “only dose makes the poison,” as coined in Paracelsus’ Law; (2) and the potential of the anticancer methotrexate to treat malaria, thus demonstrating that the opportunity exists to discover new antimalarials using the anticancer pharmacopoeia.作者: Altitude 時(shí)間: 2025-3-26 23:21 作者: 殘廢的火焰 時(shí)間: 2025-3-27 01:56 作者: Lipohypertrophy 時(shí)間: 2025-3-27 08:35 作者: Generator 時(shí)間: 2025-3-27 13:15 作者: Peculate 時(shí)間: 2025-3-27 15:32
https://doi.org/10.1007/978-94-007-0791-7e obtained, and the NCI is totally committed to the terms of the LOC. The discovery of the anti-HIV-active compound michellamine B has emphasized the need for source countries to establish policies governing the exploration of their biological diversity for the discovery and development of novel bio作者: myopia 時(shí)間: 2025-3-27 21:48 作者: 注入 時(shí)間: 2025-3-28 00:50
Inorganic Chemistry of Vanadiumsistant parasite populations. Screening collections of African bio-extracts, to identify non-peptide ligands that target parasite GPCRs, provides local control of intellectual property rights, creating an economically sustainable platform. Revenues derived from agreements for leads for other indicat作者: Mutter 時(shí)間: 2025-3-28 06:05
Toshiyuki Moriuchi,Toshikazu Hirao, the preclinical ADME data are being used to predict human PK and safety of NCEs. As African research scientists initiate drug discovery activities, integration of PK, in the traditionally medicinal chemistry- and disease pharmacology-driven efforts, is important towards ensuring increased chances 作者: Neutral-Spine 時(shí)間: 2025-3-28 10:19 作者: Kidney-Failure 時(shí)間: 2025-3-28 11:22
Apostolos P. Fournaris,Daniel M. Heinn Botswana, the Kweneng and Ngamiland Districts. Screening results were consistently shared and discussed with indigenous knowledge holders who participated in the STN project. A survey conducted among 28 traditional healers revealed that a large majority (93%) perceived the STN approach as benefici作者: 痛苦一下 時(shí)間: 2025-3-28 16:37 作者: 傾聽 時(shí)間: 2025-3-28 22:32 作者: 青少年 時(shí)間: 2025-3-28 23:51 作者: barium-study 時(shí)間: 2025-3-29 03:20 作者: 強(qiáng)化 時(shí)間: 2025-3-29 09:57 作者: 通情達(dá)理 時(shí)間: 2025-3-29 14:34 作者: Scleroderma 時(shí)間: 2025-3-29 18:57
Tuberculosis Drug Discovery: Target Identification and Validation,ent of TB. In addition, we highlight local (South African) research programmes which have contributed to these efforts. Consistent with the significant scientific, technical and financial obstacles confronting TB research, our analysis documents the existence of very few programmes in this region th作者: PALMY 時(shí)間: 2025-3-29 19:59 作者: grieve 時(shí)間: 2025-3-30 03:47
Application of In Silico, In Vitro and In Vivo ADMET/PK Platforms in Drug Discovery,, the preclinical ADME data are being used to predict human PK and safety of NCEs. As African research scientists initiate drug discovery activities, integration of PK, in the traditionally medicinal chemistry- and disease pharmacology-driven efforts, is important towards ensuring increased chances 作者: narcotic 時(shí)間: 2025-3-30 06:58 作者: 大門在匯總 時(shí)間: 2025-3-30 09:45
,“Now I Heal with Pride”—The Application of Screens-to-Nature Technology to Indigenous Knowledge Sysn Botswana, the Kweneng and Ngamiland Districts. Screening results were consistently shared and discussed with indigenous knowledge holders who participated in the STN project. A survey conducted among 28 traditional healers revealed that a large majority (93%) perceived the STN approach as benefici作者: Infant 時(shí)間: 2025-3-30 12:55 作者: 娘娘腔 時(shí)間: 2025-3-30 16:47
Random and Rational Approaches to HIV Drug Discovery in Africa,and development of novel inhibitors that may improve treatment strategies and overcome new challenges that have arisen. This chapter focuses on the discovery phase of the HIV drug discovery and development pipeline and describes the contribution and progress made by African scientists and research l作者: 溫室 時(shí)間: 2025-3-30 22:31 作者: amplitude 時(shí)間: 2025-3-31 03:43
